RxDoctor Payments Data

Paul Rice

Family · Dandridge, TNNPI 1346766169

Payments from drug & device makers

$6,975in general payments, 2019–2025

Across 427 payments — averaging $16.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$1K
  • Novo Nordisk$1K
  • AbbVie$579
  • Pfizer$509
  • Boehringer Ingelheim$428
  • AstraZeneca$344
  • plus $3K from 35 others

What the payments were for

  • Food & beverage$6,975100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,975 in reported general payments places this provider in the 90th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$84,291
Medicare patients
389
Services billed
3,664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab11$88,637
OzempicSemaglutide29$35,525
MounjaroTirzepatide27$34,743
EliquisApixaban31$27,549
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$24,466
LinzessLinaclotide28$20,923
JardianceEmpagliflozin12$14,548
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$7,055
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen185$4,985
Dexlansoprazole DrDexlansoprazole13$2,662
Albuterol Sulfate HfaAlbuterol Sulfate98$2,324
Lantus SolostarInsulin Glargine,hum.Rec.Anlog13$2,210
Cefdinir120$2,106
Omeprazole99$1,910
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen59$1,752

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,071$35,52529 claims
Lilly USA, LLCMounjaro$283$34,74327 claims
PfizerEliquis, Paxlovid$509$28,94567 claims
GSKTrelegy Ellipta$1,303$24,46619 claims
AbbVieLinzess, Synthroid$579$22,09242 claims
Boehringer IngelheimJardiance$428$14,54812 claims
AstraZenecaBreztri Aerosphere$344$7,05511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,706 family providers in Tennessee.

Other family in Dandridge

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →